secwatch.observer — SEC 8-K summary
======================================

Issuer:     Surgery Partners, Inc. (SGRY)
CIK:        0001638833
Form:       8-K
Filed at:   2026-08-10T11:32:04+00:00
Accession:  0001638833-26-000074
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Surgery Partners Q2 revenue up 2.7% to $848.9M; reaffirms FY2026 guidance
-------------------------------------------------------------------------

- Q2 revenue $848.9M, up 2.7% YoY; same-facility revenue +5.0%, cases +0.3%.
- Net loss attributable to SGRY $15.0M; Adjusted EBITDA $125.2M vs $129.0M in Q2 2025.
- FY2026 guidance reaffirmed: revenue $3.35-3.45B, Adjusted EBITDA at least $530M, excluding pending Idaho Falls divestiture.
- Pending Idaho Falls, Idaho facility divestiture subject to physician member and governing board approvals; expected to improve cash conversion and deleverage.
- Cash $216.7M, $617.8M revolver capacity; net debt/EBITDA ~4.4x; Q2 operating cash flow $59.3M vs $81.3M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638833/000163883326000074/0001638833-26-000074-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638833/000163883326000074/sgry-20260810.htm
  HTML page:      https://secwatch.observer/filing/0001638833-26-000074

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer